New Thought Leadership Paper Available Now from Trinity Life Sciences

Trinity Life Sciences, a leader in global life sciences commercialization solutions, releases a white paper entitled Global Market Access Trends: 2022 Edition that identifies the five key market access trends that life sciences executives should understand to ensure their organizations are prepared for the year ahead.

Results from a survey conducted by Trinity Life Sciences in late 2022 using a sample of 11 U.S. and 24 ex-U.S. payers demonstrates alignment on the perceived impact of most major trends identified. However, some disparity between U.S. and ex-U.S. is evident surrounding the topics of evolving evidence expectations and the level of difficulty in determining the appropriate management approach for products reviewed last year.

“Survey results show that U.S. payers are receptive to considering real-world evidence (RWE) in their review of new products, more so than their ex-U.S. counterparts,” said Nandini Hadker, Partner in the Evidence, Value, Access and Pricing practice at Trinity Life Sciences. “This signifies a real opportunity for U.S. manufacturers to provide more robust and compelling evidence as part of their submission packages as well as on-going value communications with payers, so they can really shape the value story for their product and move the needle on market access.”

“Greater net-price transparency is an ongoing goal of legislators and payers, and 2022 saw a number of reforms and regulations targeted to promote cost efficiency,” said Maximilian Hunt, Partner in the Evidence, Value, Access and Pricing practice at Trinity Life Sciences. “With ex-U.S. payers (specifically EU payers) citing difficulty in manufacturer price negotiations, other tactics such as statutory markdowns are being deployed.”

The new white paper additionally identifies an emerging trend of a continued global movement towards the adoption of biosimilars, as government policies emerge in reaction to the larger continued trend of increasing numbers of biological products’ patents expiring. Life sciences executives are welcome to download the paper by clicking here.

Trinity Life Sciences will be holding a webinar on February 16^th at 1pm ET to provide the opportunity for life sciences executives to further their understanding of the trends discussed in the white paper and ask the authors questions about the opportunities and challenges that may lie ahead. Register for the webinar by clicking here.

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With 25 years of experience, Trinity is committed to revolutionizing the commercial model by providing exceptional levels of service, powerful tools and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005333/en/